REPLIGEN CORP
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $738.3M | $634.4M | $632.4M | $801.5M | $670.5M |
| Cost of revenue | $352.0M | $359.8M | $353.9M | $345.8M | $279.3M |
| Selling, general & administrative | $290.5M | $263.4M | $218.6M | $215.8M | $183.9M |
| Research and development | $54.2M | $43.2M | $42.7M | $43.9M | $34.3M |
| Operating income | $55.2M | -$35.1M | $47.7M | $224.7M | $167.2M |
| Interest expense | $21.5M | $20.7M | $2.0M | $1.2M | $11.3M |
| Pretax income | $62.4M | -$27.0M | $56.7M | $219.1M | $153.5M |
| Income tax expense | $13.5M | -$1.5M | $21.1M | $33.2M | $25.3M |
| Net income | $48.9M | -$25.5M | $35.6M | $186.0M | $128.3M |
| Balance Sheet | |||||
| Cash and equivalents | $566.0M | $757.4M | $751.3M | $523.5M | $603.8M |
| Current assets | $1.1B | $1.1B | $1.1B | $998.1M | $931.7M |
| Total assets | $2.9B | $2.8B | $2.8B | $2.5B | $2.4B |
| Current liabilities | $135.8M | $126.8M | $164.9M | $404.2M | $375.3M |
| Total liabilities | $843.6M | $856.9M | $866.3M | $620.9M | $608.3M |
| Stockholders' equity | $2.1B | $2.0B | $2.0B | $1.9B | $1.8B |
| Cash Flow Statement | |||||
| Cash from operations | $117.4M | $175.4M | $113.9M | $172.1M | $119.0M |
| Depreciation and amortization | $39.7M | $35.0M | $37.0M | $23.9M | $16.4M |
| Stock-based compensation | $32.6M | $48.1M | $25.6M | $27.3M | $27.5M |
| Capital expenditure | $23.5M | $25.7M | $36.2M | $84.8M | $67.1M |
| Free cash flow | $93.9M | $149.7M | $77.7M | $87.2M | $51.9M |
| Share repurchases | $0 | $0 | $14.4M | $0 | $0 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 56.4M · Free float 90.9%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.